Table 5.
Overall survival analysis
| Dichotomized variables | Associated level |
OS |
|
|---|---|---|---|
| Hazard ratio (95% CI) | p-value | ||
|
Univariate analysis |
|
|
|
| Age |
> 66 years |
0.971 (0.514-1.834) |
0.9288 |
| Sex |
Male |
1.967 (1.033-3.748) |
0.0396 |
| KPS |
> 50 |
0.539 (0.283-1.029) |
0.0611 |
| Histology |
Adenocarcinoma |
0.965 (0.510-1.825) |
0.9118 |
| Presence of liver metastasis |
Yes |
0.982 (0.463-2.082) |
0.9616 |
| Use of chemotherapy before hRT |
Yes |
1.085 (0.572-2.057) |
0.8034 |
| Time from first diagnosis to hRT |
≥ 12 months |
0.804 (0.424-1.524) |
0.5037 |
| Other RT prior to hRT |
Yes |
1.411 (0.656-3.034) |
0.3785 |
| Use of any other hemostatic measure |
Yes |
1.056 (0.409-2.724) |
0.9105 |
| Bleeding cause |
Primary tumor |
1.420 (0.623-3.236) |
0.4036 |
| WHO bleeding score before hRT |
Grade 3 |
1.380 (0.728-2.617) |
0.3239 |
| Dose of hRT |
< 30 Gy |
2.669 (1.286-5.540) |
0.0084 |
| WHO bleeding score at end of hRT |
Grade 2-4 |
5.882 (2.445-13.865) |
<0.0001 |
| WHO bleeding score at end of follow-up |
Grade 2-4 |
2.006 (0.969-4.154) |
0.0609 |
|
Multivariate analysis |
|
|
|
| Sex |
Male |
1.007 (0.487-2.081) |
0.9859 |
| Dose of hRT |
< 30 Gy |
2.853 (1.360-5.987) |
0.0056 |
| WHO bleeding score at end of hRT | Grade 2-4 | 6.456 (2.645-16.202) | <0.0001 |
Abbreviations: RT=radiotherapy; hRT=hemostatic radiotherapy; KPS=Karnowsky performance score; OS=overall survival.